Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example ResearchStudy: Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

version: 29; Last updated: 2025-08-18 13:22:42+0000

Profile: StudyRegistryRecord

ResearchStudy Study Registration

  • activity: Registration submission
  • actual: true
  • period: 2018-08-15 --> (ongoing)

ResearchStudy Study Registration

  • activity: Results submission
  • actual: true
  • period: 2023-05-31 --> (ongoing)

ResearchStudy Study Registration

  • activity: Registration submission Quality Check
  • actual: true
  • period: 2018-08-17 --> (ongoing)

ResearchStudy Study Registration

  • activity: Results submission Quality Check
  • actual: true
  • period: 2023-09-20 --> (ongoing)

ResearchStudy Study Registration

  • activity: Record Verification
  • actual: true
  • period: ?? --> 2024-12

ResearchStudy Study Registration

  • activity: Update submission
  • actual: true
  • period: ?? --> 2024-12-16

ResearchStudy Study Registration

  • activity: Registration posting
  • actual: true
  • period: 2018-08-21 --> (ongoing)

ResearchStudy Study Registration

  • activity: Results posting
  • actual: true
  • period: 2023-09-22 --> (ongoing)

ResearchStudy Study Registration

  • activity: Primary outcome data collection
  • actual: true
  • period: ?? --> 2022-05-31

ResearchStudy Study Registration

  • activity: Update posting
  • actual: true
  • period: ?? --> 2025-01-03

Artifact Author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

ArtifactPublicationStatus: Active

url: https://fevir.net/resources/ResearchStudy/367879

identifier: FEvIR Object Identifier/367879, https://clinicaltrials.gov/NCT03640312 (use: official, ), 202203097-STU00205834, FEvIR Linking Identifier/NCT03640312 FHIR Transform

name: NCT03640312_FHIR_Transform

title: Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

label

type: Official title

value: A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (QUARTET USA)

label

type: Acronym

value: QUARTET USA

citeAs:

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367879. Revised 2025-08-18. Available at: https://fevir.net/resources/ResearchStudy/367879. Computable resource at: https://fevir.net/resources/ResearchStudy/367879#json.

relatesTo

type: Transforms

target: https://clinicaltrials.gov/api/v2/studies/NCT03640312?format=json

relatesTo

type: Transformed With

target: null @ https://fevir.net/resources/Project/29885

relatesTo

type: Cites

target: Baldridge AS, Huffman MD, Lazar D, Abbas H, Flowers FM, Quintana A, Jackson A, Khan SS, Chopra A, Vu M, Tripathi P, Jacobson T, Sanuade OA, Kandula NR, Persell SD, Paparello JJ, Rosul LL, Mejia J, Lloyd-Jones DM, Chow CK, Ciolino JD. Efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA): Rationale and design for a randomized controlled trial. Am Heart J. 2022 Dec;254:183-193. doi: 10.1016/j.ahj.2022.09.004. Epub 2022 Sep 15.

relatesTo

type: Documentation

target: application/pdf @ https://cdn.clinicaltrials.gov/large-docs/12/NCT03640312/Prot_001.pdf

relatesTo

type: Documentation

target: application/pdf @ https://cdn.clinicaltrials.gov/large-docs/12/NCT03640312/SAP_002.pdf

relatesTo

type: Documentation

target: application/pdf @ https://cdn.clinicaltrials.gov/large-docs/12/NCT03640312/ICF_000.pdf

status: Active

primaryPurposeType: Treatment

phase: Phase 2

studyDesign: Design Masking: Quadruple, Blinding of study participants, Blinding of intervention providers, Blinding of data analysts, Blinding of outcome assessors, randomized assignment, Parallel cohort design, interventional research

condition: Hypertension

keyword: Hypertension, Blood Pressure

descriptionSummary:

To investigate, in a double-blind randomized controlled trial, whether initiating treatment with ultra-low-dose quadruple-combination therapy ("LDQT") will lower office blood pressure more effectively, and with fewer side effects, compared to initiating standard dose monotherapy as per current guidelines in patients with hypertension.

Primary hypothesis: A combination pill comprising four types of blood pressure lowering medications, each at one-quarter standard doses, will lower office blood pressure more effectively than initiating patients with standard dose monotherapy as per contemporary clinical practice guideline recommendations.

description:

This trial will investigate whether initiating treatment with ultra-low-dose quadruple-combination therapy (LDQT; including candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) will lower automated office blood pressure and 24-hour ambulatory blood pressure at 12 weeks more effectively, and with no increase in side effects, compared to initiating standard dose monotherapy (candesartan 8 mg) in adults with raised blood pressure (SBP>130 mmHg or DBP>80 mmHg) and without cardiovascular disease. Our preliminary data from a short-term (4-week) crossover trial of 18 participants suggest that LDQT lowers office blood pressure by 22/13 mmHg on average compared with placebo with no difference in serious adverse events. Effects on 24-hour ambulatory blood pressure were similar.

The investigators will perform this phase II, single site, randomized controlled trial in a network of federally qualified health centers in Chicago because this population bears a disproportionate burden of blood pressure related diseases, and the investigators have previously successfully conducted clinical studies in this population.

While the investigators hypothesize this intervention will be easily implemented and efficacious for all patients and clinicians, the investigators will explore variation in treatment effect by potential moderating variables, including age, sex, race/ethnicity, and health literacy level. Beyond examining efficacy, the investigators also plan to assess feasibility of implementing this intervention in a clinical setting by simultaneously evaluating implementation outcomes of acceptability, preferences, and lessons of LDQT among patients and clinicians.

site:

classifier: IPDSharing: Yes, IPDSharingDescription: Individual participant data will be shared through NHLBI BioLINCC., IPDSharingInfoType: Study Protocol, IPDSharingInfoType: Statistical Analysis Plan (SAP), IPDSharingInfoType: Informed Consent Form (ICF), IPDSharingInfoType: Clinical Study Report (CSR), IPDSharingInfoType: Analytic Code, IPDSharingTimeFrame: Data will be available within 1 year of study conclusion., IPDSharingAccessCriteria: Access to study data will be managed through NHLBI BioLINCC, Has Results: True, Oversight Classifier: oversightHasDmc True, Oversight Classifier: isFdaRegulatedDrug True, Oversight Classifier: isFdaRegulatedDevice False, AgreementPISponsorEmployee: False, AgreementRestrictiveAgreement: False

associatedParty

name: Washington University School of Medicine

role: Sponsor

classifier: OTHER

associatedParty

name: Mark Huffman

role: Principal investigator

party: PractitionerRole

associatedParty

name: Washington University School of Medicine

role: Lead sponsor

classifier: OTHER

associatedParty

name: ACCESS Community Health Network

role: Collaborator

classifier: OTHER

associatedParty

name: University of Sydney

role: Collaborator

classifier: OTHER

associatedParty

name: Mark D Huffman, PhD, MD

role: Principal investigator

party: Northwestern University Feinberg School of Medicine

associatedParty

name: Jody D Ciolino, PhD

role: Principal investigator

party: Overall Study Officials:

progressStatus

state: Completed

progressStatus

state: Overall study

actual: true

period: 2019-08-30 --> 2024-07-31

Recruitments

-ActualNumberEligibility
*62NCT03640312 Eligibility Criteria

comparisonGroup

eligibility: QUARTET LDQT: Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.

comparisonGroup

eligibility: Candesartan: Patients randomized to the comparison arm will take a once daily 8mg candesartan.

objective

type: Primary

OutcomeMeasures

-NameTypeDescriptionEndpoint
*Change in Mean Systolic Blood PressurePrimary

Mean change (from baseline) in automated office systolic blood pressure adjusted for baseline values.

EvidenceVariable Change in Mean Systolic Blood Pressure (NCT03640312)

objective

type: Secondary

outcomeMeasure

name: Mean Systolic Blood Pressure

type: Secondary

description:

Mean automated office systolic blood pressure adjusted for baseline values.

endpoint: EvidenceVariable Mean Systolic Blood Pressure (NCT03640312)

outcomeMeasure

name: Change in Mean Diastolic Blood Pressure

type: Secondary

description:

Mean change (from baseline) in automated office diastolic blood pressure adjusted for baseline values.

endpoint: EvidenceVariable Change in Mean Diastolic Blood Pressure (NCT03640312)

outcomeMeasure

name: Mean Diastolic Blood Pressure

type: Secondary

description:

Mean automated office diastolic blood pressure adjusted for baseline values.

endpoint: EvidenceVariable Mean Diastolic Blood Pressure (NCT03640312)

outcomeMeasure

name: Proportion of Patients With Hypertension Control

type: Secondary

description:

Proportion of patients with hypertension control (percent with SBP < 130 mmHg and DBP <80 mmHg).

endpoint: EvidenceVariable Proportion of Patients With Hypertension Control (NCT03640312)

outcomeMeasure

name: Number of Patients Requiring Step up Treatment

type: Secondary

description:

Number of patients requiring step-up treatment.

endpoint: EvidenceVariable Number of Patients Requiring Step up Treatment (NCT03640312)

outcomeMeasure

name: Proportion of Patients With Adverse Event Free Hypertension Control

type: Secondary

description:

Proportion of patients with adverse event free hypertension control (percent with SBP < 130 mmHg and DBP <80 mmHg).

endpoint: EvidenceVariable Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312)

outcomeMeasure

name: Medication Adherence

type: Secondary

description:

Medication adherence defined by objective pill counts

endpoint: EvidenceVariable Medication Adherence (NCT03640312)

outcomeMeasure

name: Health-related Quality of Life

type: Secondary

description:

Mean change (from baseline) in health-related quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health instrument. PROMIS Global Health is a gauge of general health-care related quality of life. Possible PROMIS Global Physical Health and Global Mental Health scores range from 0-20, with 20 indicating best possible state of health. Raw scores are converted to T-scores to compare to a standardized population. A PROMIS T-score of 50 represents the mean of the population (SD = 10). Higher values here also indicate better health. A positive change in T score, as reported in this outcome measure, would represent an improvement in Global Physical Health or Global Mental Health at 12 weeks compared to baseline.

endpoint: EvidenceVariable Health-related Quality of Life (NCT03640312)

outcomeMeasure

name: Change in Mean Systolic Blood Pressure

type: Secondary

description:

Mean change (from baseline) in automated office systolic blood pressure adjusted for baseline values.

endpoint: EvidenceVariable Change in Mean Systolic Blood Pressure (NCT03640312)

objective

type: Exploratory

outcomeMeasure

name: Percentage of Participants With Serious Adverse Events (SAEs)

type: Exploratory

description:

Percentage of participants with any Serious Adverse Events (SAE) according to Good Clinical Practice definition: adverse events that result in death, are life threatening, require hospitalization or prolong existing hospitalization, result in persistent disability, result in congenital anomaly or birth defect, or unimportant medical event that requires intervention to prevent any of the above.

endpoint: EvidenceVariable Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312)

outcomeMeasure

name: Percentage of Participants With Potentially Related Adverse Events

type: Exploratory

description:

Percentage of participants with occurrence of any potentially related adverse event (pre-specified as in study procedures). Defined as: At least possibly related to study drug.

endpoint: EvidenceVariable Percentage of Participants With Potentially Related Adverse Events (NCT03640312)

outcomeMeasure

name: Rate of Adverse Events of Special Interest

type: Exploratory

description:

Rate of pre-specified adverse events that are known side effects of active ingredients at the participant level.

endpoint: EvidenceVariable Rate of Adverse Events of Special Interest (NCT03640312)

outcomeMeasure

name: Mean Change in Serum Potassium

type: Exploratory

description:

Mean change (from baseline) in continuous serum potassium.

endpoint: EvidenceVariable Mean Change in Serum Potassium (NCT03640312)

outcomeMeasure

name: Mean Change in Serum Sodium

type: Exploratory

description:

Mean change (from baseline) in continuous serum sodium.

endpoint: EvidenceVariable Mean Change in Serum Sodium (NCT03640312)

outcomeMeasure

name: Mean Change in Blood Urea Nitrogen

type: Exploratory

description:

Mean change (from baseline) in continuous blood urea nitrogen.

endpoint: EvidenceVariable Mean Change in Blood Urea Nitrogen (NCT03640312)

outcomeMeasure

name: Mean Change in Serum Creatinine

type: Exploratory

description:

Mean change in continuous serum creatinine.

endpoint: EvidenceVariable Mean Change in Serum Creatinine (NCT03640312)

result: Results Section for NCT03640312


Generated Narrative: EvidenceVariable #NCT03640312-drug------quartet-ldqt

name: NCT03640312_drug______quartet_ldqt

title: QUARTET LDQT

status: Active

description:

Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.

handling: boolean variable

classifier: Intervention Type: DRUG


Generated Narrative: EvidenceVariable #NCT03640312-drug------candesartan

name: NCT03640312_drug______candesartan

title: Candesartan

status: Active

description:

Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.

handling: boolean variable

classifier: Intervention Type: DRUG


Generated Narrative: Group #NCT03640312-comparison-group-0

Artifact Author: Computable Publishing®: [System]-to-FEvIR Converter:

identifier: FEvIR Linking Identifier/NCT03640312-comparison-group-0

title: NCT03640312 Comparison Group: QUARTET LDQT

status: Active

description:

Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.

membership: Conceptual

code: Experimental

Characteristics

-CodeValue[x]Exclude
*Exposed toDrug: QUARTET LDQTfalse

Generated Narrative: Group #NCT03640312-comparison-group-1

Artifact Author: Computable Publishing®: [System]-to-FEvIR Converter:

identifier: FEvIR Linking Identifier/NCT03640312-comparison-group-1

title: NCT03640312 Comparison Group: Candesartan

status: Active

description:

Patients randomized to the comparison arm will take a once daily 8mg candesartan.

membership: Conceptual

code: Active Comparator

Characteristics

-CodeValue[x]Exclude
*Exposed toDrug: Candesartanfalse

Generated Narrative: PractitionerRole #NCT03640312-ResponsibleParty-0

practitioner: Mark Huffman

organization: Washington University School of Medicine

code: Professor of Medicine and Global Health Center Co-Director


Generated Narrative: Location #NCT03640312-Location-0

name: ACCESS Martin T. Russo Family Health Center

address: Bloomingdale Illinois 60108 United States

Positions

-LongitudeLatitude
*-88.080941.95753

Generated Narrative: Location #NCT03640312-Location-1

name: Ashland Family Health Center

address: Chicago Illinois 60609 United States

Positions

-LongitudeLatitude
*-87.6500541.85003